BE XR OD vs IR BID - which Cmax for IR? [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-05-11 06:29 (298 d 06:18 ago) – Posting: # 21417
Views: 1,922

» I would like to have the help of the forum participants on a tricky question, ie which IR Cmax should be considered to assess the potential bioequivalence between an IR formulation administered BID and an XR formulation administered OD on day 1 and at steady-state. This is for a submission to FDA.

Not sure if the following will answer your Q exactly and whether it still exists on FDA website (or they blacked out the results):
Look for Ultram ER at [email protected]
Similar approach (Don't ask how I know :))

J

Complete thread:

Activity
 Admin contact
21,366 posts in 4,462 threads, 1,493 registered users;
online 9 (0 registered, 9 guests [including 3 identified bots]).
Forum time: Friday 11:47 CET (Europe/Vienna)

The statistician has no magic touch by which
he may come in at the stage of tabulation
and make something of nothing.    W. Edwards Deming

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5